Project POKE: Developing a STEM Community to Offset Learning Loss Amidst COVID Pandemic Through Aerospace Technologies Project-Based Learning in Hawaii\u27s K-12 Classrooms

Project POKE (Providing an Opportunity for the Keiki in Engineering) is a unique opportunity for middle and high school keiki (‘children’ in Hawaiian) in Hawaii to gain hands-on aerospace experience through interaction with a 1U CubeSat kit. The focus of the project is to build a STEM community based on collaboration and project-based learning to offset learning loss amidst the COVID-19 pandemic. The Project POKE program includes an educator course, CubeSat kit, collaborative digital space, open-ended design challenge, and symposium. Middle and high school teachers concurrently participate in the program’s educator course and meet with their students to teach the provided content. Project POKE builds off of the Artemis CubeSat Kit while adapting the educator course materials to K-12 education. Students are challenged to develop a mission concept to study a problem affecting their community using a CubeSat and present their design concept to STEM professionals at the culminating symposium. The first iteration of the program was completed in the 2021-2022 school year with 14 teachers and over 100 students. Surveyed participants indicated positive sentiment and several learning outcomes upon completing the program. Project POKE creates a diversified STEM community in Hawaii, while demystifying space science and aerospace engineering

University of Hawaii\u27s Spaceflight-Ready, Low-Cost, Open-Source, Educational Artemis CubeSat Kit

The Artemis CubeSat Kit is a spaceflight-ready, low-cost, educational 1U CubeSat kit, which acts as a foundation enabler in aerospace engineering education and commercializing small satellites. The hardware kit accompanies a standalone Spacecraft Mission Design curriculum in the public domain, which includes a self-guided course outline, textbook, and digital lab modules. Funded by NASA\u27s Artemis Student Challenge Program, the Kit is developed and maintained by students attending the University of Hawaii at Manoa and supervised by the Hawaii Space Flight Laboratory (HSFL). The purpose of the Artemis CubeSat Kit and accompanying curriculum is to provide educational accessibility for university-level students and faculty interested in designing, building, and flying their own small satellite missions. This paper describes the technical design of the Artemis 1U CubeSat, the topology of the standalone curriculum, and the lessons learned by the team while developing the Artemis CubeSat Kit

Ke Ao: A Low-Cost 1U CubeSat for Aerospace Education and Research in Hawaii

The Ke Ao satellite is a low-cost 1U CubeSat designed and developed by an undergraduate team of engineering students at the University of Hawaii at Manoa (UHM) in collaboration with the Hawaii Space Flight Laboratory (HSFL). The primary goal of the mission is to take one or more pictures from space and automatically identify the Hawaiian Islands using Machine Learning Algorithms - this will demonstrate improved onboard operational autonomy in space. A secondary goal of this project is to promote Aerospace Education and Workforce training in Hawaii. The Ke Ao project was inspired by the Hiapo CubeSat initiative of the Hawaii Science and Technology Museum as a unique platform used to provide engaging meaningful hands-on STEM curriculum for Hawaii students K-12. The realization that low-cost flight hardware, in the order of ～$10k, is practically non-existent, and therefore the barrier to launch a flight-capable CubeSat is still high for small organizations and schools with low budgets. The Ke Ao project started in the Fall of 2019 with the Vertically Integrated Project (VIP) Aerospace Technologies with Electrical, Mechanical, and Computer Science Engineering Students at UH and continued to be facilitated under the Mechanical Engineering Senior Design Course within the College of Engineering throughout the year of 2020. The project was impacted by the global COVID-19 pandemic but this enabled the student team to improve on the design and simulations. Hiapo and Ke Ao also inspired the NASA Artemis CubeSat Kit project being developed at the HSFL. The Artemis CubeSat Kit will be used as an educational tool for teaching aerospace and distribution in the public domain. The development of these three CubeSats allowed for synergistic development and multipurpose designs and gave the students a wide breadth of design experiences. This paper will expand on the design and development for the main objectives for Ke Ao (1) take one or more pictures of the Hawaiian Islands from space; (2) cost shall be no more than$10,000 with built parts; and (3) launch-ready via the NASA CSLI application and requirements. To address these objectives Ke Ao uses spaceflight capable but low-cost hardware flown in previous CubeSat missions and consists of seven primary subsystems: Attitude Determination and Control System, Communications, Electrical Power Systems, On-Board Computer and Flight Software, Payload, Structure and Mechanisms, and Thermal Control Systems. Ke Ao will use onboard magnetic torquers to control the attitude of the payload and take pictures of the Hawaiian Islands. The data will be transmitted to the HSFL ground stations in Hawaii and through the SatNOGS ground station network across the World. Ke Ao’s mission and primary goals are in line with the 2018 NASA Strategic Plan’s Strategic Objective 3.3 to Inspire and Engage the Public in Aeronautics, Space, and Science and contribute to the Nation’s science literacy

NEUTRON-1 Mission: Low Earth Orbit Neutron Flux Detection and COSMOS Mission Operations Technology Demonstration

The Neutron-1 mission is scheduled to launch on ELaNa 25 during the Fall of 2019. The 3U CubeSat will measure low energy neutron flux in Low Earth Orbit (LEO). The CubeSat was developed by the Hawaii Space Flight Laboratory (HSFL) at the University of Hawaii at Manoa (UHM). The science payload, a small neutron detector developed by Arizona State University (ASU) for the LunaH-Map, will focus on measurements of low energy secondary neutrons, one of the components of the LEO neutron environment. In addition, this mission presents an excellent opportunity to establish flight heritage and demonstrate the technological capabilities of the NASA EPSCoR funded Comprehensive Open-architecture Solution for Mission Operations Systems (COSMOS, http://cosmos-project.org ). COSMOS is an open source set of tools that is being developed at HSFL as an integrated operations solution (including flight software, ground station operations, and mission operations center) for Small Satellite missions. It is intended to enable/facilitate SmallSat mission operations at universities with limited budgets and short schedules

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

© 2020 Elsevier Ltd. All rights reserved.Background: Hereditary transthyretin-mediated amyloidosis is a rare, inherited, progressive disease caused by mutations in the transthyretin (TTR) gene. We assessed the safety and efficacy of long-term treatment with patisiran, an RNA interference therapeutic that inhibits TTR production, in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Methods: This multicentre, open-label extension (OLE) trial enrolled patients at 43 hospitals or clinical centres in 19 countries as of Sept 24, 2018. Patients were eligible if they had completed the phase 3 APOLLO or phase 2 OLE parent studies and tolerated the study drug. Eligible patients from APOLLO (patisiran and placebo groups) and the phase 2 OLE (patisiran group) studies enrolled in this global OLE trial and received patisiran 0·3 mg/kg by intravenous infusion every 3 weeks with plans to continue to do so for up to 5 years. Efficacy assessments included measures of polyneuropathy (modified Neuropathy Impairment Score +7 [mNIS+7]), quality of life, autonomic symptoms, nutritional status, disability, ambulation status, motor function, and cardiac stress, with analysis by study groups (APOLLO-placebo, APOLLO-patisiran, phase 2 OLE patisiran) based on allocation in the parent trial. The global OLE is ongoing with no new enrolment, and current findings are based on the interim analysis of the patients who had completed 12-month efficacy assessments as of the data cutoff. Safety analyses included all patients who received one or more dose of patisiran up to the data cutoff. This study is registered with ClinicalTrials.gov, NCT02510261. Findings: Between July 13, 2015, and Aug 21, 2017, of 212 eligible patients, 211 were enrolled: 137 patients from the APOLLO-patisiran group, 49 from the APOLLO-placebo group, and 25 from the phase 2 OLE patisiran group. At the data cutoff on Sept 24, 2018, 126 (92%) of 137 patients from the APOLLO-patisiran group, 38 (78%) of 49 from the APOLLO-placebo group, and 25 (100%) of 25 from the phase 2 OLE patisiran group had completed 12-month assessments. At 12 months, improvements in mNIS+7 with patisiran were sustained from parent study baseline with treatment in the global OLE (APOLLO-patisiran mean change -4·0, 95 % CI -7·7 to -0·3; phase 2 OLE patisiran -4·7, -11·9 to 2·4). Mean mNIS+7 score improved from global OLE enrolment in the APOLLO-placebo group (mean change from global OLE enrolment -1·4, 95% CI -6·2 to 3·5). Overall, 204 (97%) of 211 patients reported adverse events, 82 (39%) reported serious adverse events, and there were 23 (11%) deaths. Serious adverse events were more frequent in the APOLLO-placebo group (28 [57%] of 49) than in the APOLLO-patisiran (48 [35%] of 137) or phase 2 OLE patisiran (six [24%] of 25) groups. The most common treatment-related adverse event was mild or moderate infusion-related reactions. The frequency of deaths in the global OLE was higher in the APOLLO-placebo group (13 [27%] of 49), who had a higher disease burden than the APOLLO-patisiran (ten [7%] of 137) and phase 2 OLE patisiran (0 of 25) groups. Interpretation: In this interim 12-month analysis of the ongoing global OLE study, patisiran appeared to maintain efficacy with an acceptable safety profile in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Continued long-term follow-up will be important for the overall assessment of safety and efficacy with patisiran.info:eu-repo/semantics/publishedVersio

Empagliflozin in Patients with Chronic Kidney Disease

Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to < 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of & GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P < 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo